These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31228190)

  • 1. Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.
    Hall KT; Kessler T; Buring JE; Passow D; Sesso HD; Zee RYL; Ridker PM; Chasman DI; Schunkert H
    Eur Heart J; 2019 Nov; 40(41):3385-3392. PubMed ID: 31228190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
    Kessler T; Wolf B; Eriksson N; Kofink D; Mahmoodi BK; Rai H; Tragante V; Åkerblom A; Becker RC; Bernlochner I; Bopp R; James S; Katus HA; Mayer K; Munz M; Nordio F; O'Donoghue ML; Sager HB; Sibbing D; Solakov L; Storey RF; Wobst J; Asselbergs FW; Byrne RA; Erdmann J; Koenig W; Laugwitz KL; Ten Berg JM; Wallentin L; Kastrati A; Schunkert H
    Cardiovasc Res; 2019 Aug; 115(10):1512-1518. PubMed ID: 30768153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Characterization of the
    Kessler T; Wobst J; Wolf B; Eckhold J; Vilne B; Hollstein R; von Ameln S; Dang TA; Sager HB; Moritz Rumpf P; Aherrahrou R; Kastrati A; Björkegren JLM; Erdmann J; Lusis AJ; Civelek M; Kaiser FJ; Schunkert H
    Circulation; 2017 Aug; 136(5):476-489. PubMed ID: 28487391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease.
    Hall KT; Nelson CP; Davis RB; Buring JE; Kirsch I; Mittleman MA; Loscalzo J; Samani NJ; Ridker PM; Kaptchuk TJ; Chasman DI
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2160-7. PubMed ID: 25035343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling.
    Emdin CA; Khera AV; Klarin D; Natarajan P; Zekavat SM; Nomura A; Haas M; Aragam K; Ardissino D; Wilson JG; Schunkert H; McPherson R; Watkins H; Elosua R; Bown MJ; Samani NJ; Baber U; Erdmann J; Gormley P; Palotie A; Stitziel NO; Gupta N; Danesh J; Saleheen D; Gabriel S; Kathiresan S
    Circulation; 2018 Jan; 137(3):222-232. PubMed ID: 28982690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between GUCY1A3 genetic polymorphisms and large artery atherosclerotic stroke risk in Chinese Han population: a case-control study.
    Li JL; Liu LY; Jiang DD; Jiang YY; Zhou GQ; Mo DC; Luo M
    Lipids Health Dis; 2019 Dec; 18(1):233. PubMed ID: 31883534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulators of the soluble guanylyl cyclase: promising functional insights from rare coding atherosclerosis-related GUCY1A3 variants.
    Wobst J; von Ameln S; Wolf B; Wierer M; Dang TA; Sager HB; Tennstedt S; Hengstenberg C; Koesling D; Friebe A; Braun SL; Erdmann J; Schunkert H; Kessler T
    Basic Res Cardiol; 2016 Jul; 111(4):51. PubMed ID: 27342234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
    Wolff T; Miller T; Ko S
    Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
    Pallikadavath S; Ashton L; Brunskill NJ; Burton JO; Gray LJ; Major RW
    Eur J Prev Cardiol; 2022 Feb; 28(17):1953-1960. PubMed ID: 34448849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
    Gelbenegger G; Postula M; Pecen L; Halvorsen S; Lesiak M; Schoergenhofer C; Jilma B; Hengstenberg C; Siller-Matula JM
    BMC Med; 2019 Nov; 17(1):198. PubMed ID: 31679516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin for Primary Prevention of Cardiovascular Events.
    Abdelaziz HK; Saad M; Pothineni NVK; Megaly M; Potluri R; Saleh M; Kon DLC; Roberts DH; Bhatt DL; Aronow HD; Abbott JD; Mehta JL
    J Am Coll Cardiol; 2019 Jun; 73(23):2915-2929. PubMed ID: 31196447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
    Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
    Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
    JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
    Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K
    Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
    Kunutsor SK; Seidu S; Khunti K
    Diabet Med; 2017 Mar; 34(3):316-327. PubMed ID: 27086572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
    Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
    N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.